Global Interventional Radiology Market by Type (Interventional Oncology Devices, Interventional Nephrology Devices, Interventional Cardiology Devices), by Application (Cancer Treatment, Vascular Access, Pain Management), by End-Use Industry (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers), and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Interventional Radiology Market was valued at USD 17.8 Billion in 2024-e and will surpass USD 30.1 Billion by 2030; growing at a CAGR of 9.2% during 2025 - 2030.

The Interventional Radiology Market is experiencing significant growth, driven by the increasing demand for minimally invasive procedures in the treatment of various conditions, including cancer, vascular diseases, and pain management. Interventional radiology (IR) utilizes advanced imaging techniques to guide the physician in performing precise procedures, leading to quicker recovery times, reduced complications, and less pain for patients. The rising preference for minimally invasive treatments and the development of advanced IR technologies are fueling market expansion.

Technological advancements, such as the integration of artificial intelligence (AI) and robotics in interventional procedures, are transforming the landscape. The growing prevalence of chronic diseases, including cancer and cardiovascular conditions, is also contributing to the increasing adoption of interventional radiology techniques. As healthcare providers seek more effective and cost-efficient treatments, IR offers a solution that addresses these needs while improving patient outcomes.

Interventional Oncology Devices Are Largest Segment Owing to Rising Cancer Incidence

Interventional oncology devices represent the largest segment within the interventional radiology market. These devices are used in the treatment of various types of cancer, offering a minimally invasive alternative to traditional surgical methods. Procedures such as tumor ablation, chemoembolization, and radioembolization are guided by imaging technologies, enabling more precise targeting of tumors. The growth in this segment is closely linked to the rising incidence of cancer worldwide and the increasing preference for less invasive treatments that minimize patient recovery time.

Technological advancements in interventional oncology devices, such as the development of more efficient ablation tools and embolization agents, continue to improve treatment efficacy. The demand for these devices is expected to grow as new applications emerge and as more patients seek options that provide fewer complications compared to traditional surgical interventions. With continued research and development in this area, the market for interventional oncology devices is poised for sustained growth.

Interventional Nephrology Devices Are Fastest-Growing Segment Due to Increasing Renal Disease Prevalence

Interventional nephrology devices represent the fastest-growing segment within the interventional radiology market. These devices are essential for the treatment of chronic kidney diseases, dialysis access, and other renal disorders. Interventional nephrology techniques, such as percutaneous renal biopsies and dialysis catheter insertions, are becoming increasingly common due to their minimally invasive nature and ability to offer faster recovery times compared to traditional surgical methods.

The rapid growth in this segment is largely attributed to the rising prevalence of chronic kidney diseases, which are a leading cause of morbidity worldwide. Additionally, advancements in dialysis technology and the growing adoption of dialysis access procedures are expected to further boost the demand for interventional nephrology devices. As the global population ages, the demand for renal care is anticipated to grow, driving innovation and growth in this market segment.

Cancer Treatment Leads the Application Segment Due to Increasing Cancer Incidence

Cancer treatment is the largest application segment within the interventional radiology market, driven by the growing global burden of cancer. Interventional radiology plays a vital role in the diagnosis and treatment of cancer, with procedures such as biopsy, ablation, and embolization being critical components of oncological care. These minimally invasive treatments are preferred due to their effectiveness, reduced recovery times, and the ability to treat patients who may not be suitable candidates for traditional surgery.

The expansion of interventional oncology treatments, coupled with the development of new techniques and devices, is further accelerating the demand for interventional radiology services in oncology. As cancer rates continue to rise globally, the need for advanced, less invasive treatment options will continue to drive the growth of this segment. The integration of advanced imaging technologies and targeted therapies will further enhance the role of interventional radiology in cancer treatment.

Hospitals Dominate the End-Use Industry Due to High Procedure Volumes and Advanced Infrastructure

Hospitals are the largest end-use industry segment for interventional radiology, owing to their advanced healthcare infrastructure and the high volume of interventional procedures performed. Hospitals are the primary settings for the treatment of complex conditions such as cancer, cardiovascular diseases, and renal disorders, all of which benefit from the use of interventional radiology techniques. The growing availability of specialized IR departments within hospitals and the continuous improvement in radiological equipment and technologies contribute to the dominance of this segment.

Moreover, hospitals are at the forefront of adopting new interventional radiology procedures, integrating the latest technologies such as robotic systems, AI, and real-time imaging to improve patient outcomes. The increasing demand for minimally invasive treatments in hospital settings, alongside ongoing investments in advanced imaging systems, ensures that hospitals will continue to drive the growth of the interventional radiology market.

North America Leads the Market Due to Advanced Healthcare Systems and High Disease Burden

North America is the largest regional market for interventional radiology, driven by the presence of advanced healthcare systems, a high volume of interventional procedures, and a significant disease burden. The United States, in particular, has well-established infrastructure and healthcare networks capable of offering a wide range of interventional radiology services. The growing adoption of minimally invasive procedures and the increasing prevalence of diseases such as cancer, kidney disease, and cardiovascular conditions are further fueling the demand for interventional radiology in this region.

The region also benefits from ongoing investments in research and development of new interventional techniques and devices, as well as a strong regulatory framework supporting innovation. Additionally, the growing number of specialized IR centers and the integration of cutting-edge imaging technologies contribute to North America’s leadership in the interventional radiology market.

Competitive Landscape and Leading Companies

The Interventional Radiology Market is highly competitive, with several key players leading the space. Prominent companies in the market include Medtronic, Siemens Healthineers, Johnson & Johnson, Boston Scientific Corporation, and Abbott Laboratories. These companies dominate the market through their extensive product portfolios, strong distribution networks, and continuous innovation in interventional radiology technologies.

To maintain competitive advantage, companies are focusing on the development of advanced devices, integration of AI and machine learning technologies in imaging systems, and expanding their market reach through strategic partnerships and acquisitions. With the growing demand for minimally invasive treatments and the expansion of interventional radiology applications, these companies are expected to continue to drive market innovation and lead the competitive landscape.

Recent Developments:

• Medtronic launched a new line of biopsy needles designed for improved precision and minimal discomfort.
• Stryker Corporation introduced a next-generation angioplasty balloon aimed at improving cardiovascular interventions.
• Philips Healthcare announced an innovative imaging system for enhanced guidance in interventional radiology procedures.
• Boston Scientific received FDA approval for their new interventional oncology device aimed at liver cancer treatment.
• Cook Medical expanded their portfolio with new vascular access devices designed to improve patient outcomes in minimally invasive procedures.

List of Leading Companies:

• Medtronic PLC
• Johnson & Johnson (DePuy Synthes)
• Stryker Corporation
• Becton, Dickinson and Company (BD)
• Terumo Corporation
• Abbott Laboratories
• Boston Scientific Corporation
• Philips Healthcare
• Cook Medical
• Cardinal Health, Inc.
• Conmed Corporation
• Hologic, Inc.
• Smith & Nephew
• AngioDynamics
• Olympus Corporation

Report Scope: